Humanitarian and resident coordinators call

May 12
Overview of COVID-19 Vaccine Rollout

Dr. Ann Lindstrand
1,298 m doses of COVID-19 vaccine have been administered\(^1\) in 206 countries, areas, territories & economies\(^2\)

Total doses administered per 100 population\(^3\)

1,298M vaccine doses\(^1\) have been administered

COVAX has shipped 59.2M doses to 122 participants\(^4\)

Campaigns have not yet started in 14 countries, economies & territories\(^2\)

---

Note: The designations employed and the presentation of these materials do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.; (1) Source of data: Bloomberg; (2) Total of 220 countries, areas, territories & economies: 218 economies listed by World Bank + WHO Member states Cook Islands + Niue; (3) WHO COVID-19 Dashboard at https://covid19.who.int/; (4) Including donations of doses through COVAX.
Of the 15 COVID-19 vaccines now in use, AstraZeneca & Pfizer products remain the most prevalent

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Number of countries &amp; economies using the vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td>✔️ AstraZeneca - Vaxzevria / SII - Covishield</td>
<td>88</td>
</tr>
<tr>
<td>✔️ Pfizer BioNTech - Comirnaty</td>
<td>110</td>
</tr>
<tr>
<td>✔️ Beijing CNBG - BBIBP-CorV (Sinopharm)</td>
<td>62</td>
</tr>
<tr>
<td>✔️ Moderna - mRNA-1273</td>
<td>60</td>
</tr>
<tr>
<td>✔️ Gamaleya - Sputnik V</td>
<td>52</td>
</tr>
<tr>
<td>✔️ Janssen - Ad26.COV 2.5</td>
<td>43</td>
</tr>
<tr>
<td>✔️ Sinovac - CoronaVac</td>
<td>34</td>
</tr>
<tr>
<td>Bharat - Covaxin</td>
<td>9</td>
</tr>
<tr>
<td>Novavax - Covavax</td>
<td>5</td>
</tr>
<tr>
<td>Wuhan CNBG - Inactivated</td>
<td>5</td>
</tr>
<tr>
<td>CanSino - Ad5-nCOV</td>
<td>4</td>
</tr>
<tr>
<td>SRCVB - EpiVacCorona</td>
<td>2</td>
</tr>
<tr>
<td>Anhui ZL - Recombinant</td>
<td>1</td>
</tr>
</tbody>
</table>

38 economies are using 1 vaccine; 168 are using 2 or more vaccines

Note: (1) World Bank classification (2021) of 218 economies; The term country, used interchangeably with economy, does not imply political independence but refers to any territory for which authorities report separate social or economic statistics.

COVAX has now shipped 59.2M doses to 122 participants
Incl. 60 LMIC/LICs; 36 participants started their first campaigns thanks to COVAX doses

Note: The designations employed and the presentation of these materials do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

*Kosovo: All references to Kosovo should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

Source: COVAX, WHO COVID-19 dashboard, Our World in Data; Government websites; Press research
17.6% of doses have been administered in LICs/LMICs while they represent 46.7% of the world's population

% of COVID-19 vaccine doses administered and population by income group

Source: Our World in Data (Dec-Feb); WHO Dashboard (Mar onwards); source for income groups: World Bank. Using the latest available values for each month.
Of WHO’s 194 Member States, 180 have now started COVID-19 vaccination

WHO Member States
N= 194

180 (93%)

14 (7%)

AFRO
N= 47

40

7

AMRO
N= 35

33

2

EMRO
N= 21

21

EURO
N= 53

53

SEARO
N= 11

SEARO
N= 11

1

3

WPRO
N= 27

23

Note: (1) Burkina Faso, Burundi, Central African Republic, Chad, Eritrea, Madagascar, United Republic of Tanzania; Cuba, Haiti; (3) Democratic People’s Republic of Korea; (4) Kiribati, Vanuatu, Cook Islands, Niue

Source: WHO COVID-19 dashboard, COVAX, Our World in Data; press reports
Issues and reported challenges

**Safety**
- Translating safety communications into country FAQs and fact sheets related to AZ and J&J safety.
- Low safety reporting into regional and global databases.

**Cold chain / supply and logistics**
- Continued challenges managing and tracking multiple products arriving in countries (EUL, non-EUL, COVAX, non-COVAX).
- Challenge for non-EUL vaccines estimation of cold chain needs, no information on product characteristics.

**Costing and Financing**
- Gavi and UNICEF funding available for countries to support immediate needs for operational costs. Country slow response to Gavi’s bridge financing and to provide budgets.
- 42 countries in the pipeline to receive WB funding, funding decisions have been expedited.

**Uptake**
- Vaccine hesitancy: product specific / AZ safety concerns, among health workers and among general population (including rumors).
- Balance between reaching prioritized target populations and ensuring doses are consumed for maximum public health benefit.
- eJRF reporting status: Reporting completeness lower than usual.

**Other risks**
- Vaccination break through infections.
- Guidance document requests (from SEARO/WPRO): (i) clarification on SAGE language using vaccines with WHO/SAGE recommendation and EUL, (ii) recommendations on childhood vaccination, (iii) guideline on No-fault compensation (NFC).
Supply scenarios for round 4 allocation are being developed to re-equilibrate population coverage across participants due to supply changes

- There are three scenarios for Round 4 allocation based on variations in SII supply forecast. These scenarios have to be further reviewed given recent changes in availability for AZ doses.

- Allocation scenarios are being developed despite uncertainty on SII dose availability, as Pfizer and JnJ require at least 8 weeks lead time to prepare shipments and doses will be available in July.

- WHO has officially approved Pfizer's request to shift storage at -25 °C to -5°C for up to 2 weeks. WHO Covid-19 EUL webpages will be updated upon availability of revised WHO Product Information sheets.

- GAVI is speaking to Pfizer on possibility of adding more countries.
COVAX Facility candidate-specific supply
2021 and 2022

COVAX Available Supply, Mn doses, 2021 and 2022

- Committed doses
- Optional doses

There are currently seven vaccines in the COVAX portfolio:
1. AstraZeneca: ChAdOx1-S (recombinant) ["AZD1222"]
2. Novavax: NVX-CoV2373
3. SII: Covishield ("AZD1222")
4. SII: Covovax ("NVX-CoV2373")
5. Pfizer: BNT162b2
7. Sanofi-GSK: Recombinant Protein

**Note:**
1. “Committed doses” are doses that the COVAX Facility is required to purchase once a legally-binding agreement has been signed. “Optional doses” are doses that the COVAX Facility has the option to make a firm order commitment for in the future, but is not required to purchase.
2. Building on the recently announced memorandum of understanding with Novavax (previously shown as “Candidate A”), negotiations on the final terms of the agreement and the distribution of volumes between Novavax and the Serum Institute of India are ongoing; updates will be published in due course.
With higher numbers of doses expected for July/August, there is an urgent need for scaling up.

### Current situation (informed assumptions):

- **55 million** doses delivered in 11 weeks
- **5 million** doses run rate
- **40-60%** administered

### Non-administered doses, J&J doses, donations and perhaps more AZ doses in the pipeline for July/August:

- **30 million** +, approx., doses per month
- **75 million** + to ship per week
- **15 x** More volume to ship

### Implications:

We urgently need to move towards scale. There are major risks that achieving scale quickly in many countries will difficult. The rate of administration will also need to significantly go up.
WHO is considering additional vaccines for EUL and has already listed the Sinopharm COVID-19 vaccine for emergency use, Sinovac is set to follow soon

<table>
<thead>
<tr>
<th>SinoPharm</th>
<th>SinoVac</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Sinopharm’s EUL was granted on May 7.</td>
<td>• On the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its extraordinary meeting on 29 April 2021, draft interim guidance were developed for the Sinovac vaccine. The guidance is based on the evidence in the Background document on the CoronaVac (COVID-19) vaccine and the Background paper on COVID-19 disease and vaccines.</td>
</tr>
<tr>
<td>• WHO listed the Sinopharm COVID-19 vaccine for emergency use on May 7, giving the green light for this vaccine to be rolled out globally. The product is an inactivated vaccine with easy storage requirements that make it highly suitable for low-resource settings. It is the also first vaccine that will carry a vaccine vial monitor.</td>
<td>• Sinovac’s EUL could be granted imminently.</td>
</tr>
</tbody>
</table>

No agreement has yet been reached between the manufacturers of Sinopharm and Sinovac on the number of doses for the COVAX facility.
Financing to support COVID-19 vaccine delivery

<table>
<thead>
<tr>
<th>Funder</th>
<th>Envelope</th>
<th>Disbursed</th>
<th>Expected by July</th>
<th>Funding areas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gavi/COVAX</td>
<td>Early vaccination planning</td>
<td>$150m</td>
<td>--</td>
<td>• $60m TA / $90m CCE</td>
</tr>
<tr>
<td></td>
<td>COVAX delivery support</td>
<td>--</td>
<td>$775m</td>
<td>Provisional sub-allocations:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• $30m rapid response window</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• $620m country delivery support</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• $15m humanitarian settings</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• $40m risk mitigation measures (Vx, $$)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• $70m regional/global and innovation</td>
</tr>
<tr>
<td>World Bank</td>
<td>COVID Vaccine Delivery loans ($12B envelope)</td>
<td>--</td>
<td>$2B</td>
<td>• 17 projects approved to date</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• 70% for Vx procurement</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• 30% for delivery support to areas like demand, surge HR, CCE, monitoring</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>$4B</td>
<td>50 projects in pipeline</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Interest from countries lower than expected</td>
</tr>
<tr>
<td>USAID</td>
<td>2020 COVID Vx support</td>
<td>$75m</td>
<td>--</td>
<td>• Delivery support for 50 LIC/LMICs</td>
</tr>
<tr>
<td></td>
<td>ARC first tranche</td>
<td></td>
<td>$100m</td>
<td>• Delivery support for LIC/LMICs (countries TBD)</td>
</tr>
<tr>
<td>Asian Development Bank</td>
<td>Vaccine Initiative for Developing Asia ($9B)</td>
<td>--</td>
<td>$1B</td>
<td>• Delivery support to Indonesia, Philippines, Afghanistan, Pacific Island states</td>
</tr>
<tr>
<td>Inter-American</td>
<td>Coronavirus Vaccine Platform ($1B envelope)</td>
<td>--</td>
<td>$300m</td>
<td>• 10 projects approved in Latin America</td>
</tr>
<tr>
<td>Development Bank</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

TOTAL                    | $225M                                 | $8.2B     |                 |                                                                                                                                              |
The World Bank Group’s Board has also approved 19 projects totaling $2 billion

US$12 billion have been made available for COVID-19 vaccine procurement and related health systems strengthening and vaccine uptake interventions.

<table>
<thead>
<tr>
<th>Status &amp; Timing</th>
<th>Countries</th>
<th># of Countries</th>
<th>Amount (US$)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AFE (17): Angola, Comoros, DRC, Lesotho, Kenya, Madagascar, Malawi, Mauritius, Mozambique, Sao Tome &amp; Principe, Seychelles, South Africa, Sudan, Zambia, Zimbabwe</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AFW (16): Benin, Congo Rep of, Chad, Gabon, Ghana, Guinea, Guinea Bissau, Liberia, Mali, Mauritania, Niger, Senegal, Sierra Leone, Togo</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EAP (5): Cambodia, Indonesia, Lao PDR, Myanmar, PNG</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ECA (8): Azerbaijan, Georgia, Kosovo, Kyrgyz Rep, Montenegro, Turkmenistan, Ukraine.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>LCR (6): Bolivia, Guyana, Panama</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MNA (3): Jordan, West Bank and Gaza, Yemen</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SAR (2): Pakistan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Additional projects</td>
<td></td>
<td></td>
<td>$xx billion by mid 2021</td>
</tr>
<tr>
<td>under preparation</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
For increased transparency, visibility and accountability, countries and donors are requested to submit costing data onto the Partners Platform.

- **Countries are costing their needs and can upload their plans on the Partners Platform.**

- 9 common categories are used to align with the structure of the WHO CVIC tool and other frameworks (e.g., GAVI PEF TA, World Bank).

- Regardless of how donors manage their country request process and financial management systems, sharing of information on the Partners Platform will be through 9 common categories (incl subcategories).

- **Donors can access this information to inform support country needs and are requested to share their funding commitments.**

- Donors and partners have been requested to implement the use of these categories; visualization of donor resources will be mapped along these categories on the Platform.
Latest CRD guidance and tools are also available to support countries in their roll-out

- **Why are there extra doses in a vial**
- **Supportive supervision checklist**
- **Janssen vaccine explainer** (Short instructional video is coming soon)
- **Identifying and Managing Anaphylaxis**
- Updated: [AZ](#) and [Pfizer](#) resources (updates to SAGE interim recommendations and EUL)
- **COVID-19 vaccination in fragile/conflict settings**
- **Financing and costing FAQs**
- **CVIC promotional video**
- **Balance between reaching prioritized target populations and ensuring doses are consumed for maximum public health benefit**
- Mini cPIE resources: [The IAR methodology video](#) (available in six languages)
- **Estimating COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalizations associated with laboratory-confirmed SARS-CoV-2: an evaluation using the test-negative design**
- **Joint Note on Means to Protect Health Care from Acts of Violence in the COVID-19 Vaccination Rollout in Fragile, Conflict-affected and Vulnerable Settings**

Toolkit additions will go live on Thursdays!